A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC). The researchers will test different doses of valemetostat to find the highest dose that causes few or mild side effects in participants. After the dose is found, researchers will test it in a new group of participants to learn more about the safety of the study treatment and see if it is an effective treatment for extensive-stage SCLC.
Eligibility criteria
Qualifiers
Signed informed consent form (ICF)
Ability to comply with the study protocol as per the investigator's judgment
Age ≥ 18 years at the time of signing the ICF
Life expectancy ≥ 12 weeks
Disqualifiers
Any active uncontrolled systemic diseases or other medical conditions considered to be poorly controlled by the investigator including but not limited to bleeding diatheses, that could in the investigator's opinion, potentially interfere with completion of study procedures or interpretation of study outcomes.
Patients who receive consolidative chest radiation after completion of initial chemotherapy and immunotherapy.
Symptomatic CNS metastases
Patients with treated CNS metastases are allowed on the study if their clinical symptoms are adequately controlled and the daily dose of steroid use is equivalent to or less than 10 mg of prednisone.
Trial design
Treatments tested in this trial
- Valemetostat
- Atezolizumab
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Daiichi Sankyo
Collaborator
Source ClinicalTrials.gov